Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifoxacin

Indian Journal of Medical Research

Volumn 136, Issue 6, 2012, Pages 979-984

  Ramachandran, Geetha ^a   Hemanth Kumar, A K ^a   Srinivasan, R ^a   Geetharani, A ^a   Sugirda, P ^a   Nandhakumar, B ^a   Nandini, R ^a   Tharani, C B ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Isoniazid; Moxifoxacin; Pharmacokinetics; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; MOXIFLOXACIN; RIFAMPICIN; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; MICROBIAL SENSITIVITY TEST; TUBERCULOSIS;

ADULT; AREA UNDER CURVE; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUOROQUINOLONES; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RIFAMPIN; TUBERCULOSIS;

EID: 84873188067     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for TB? Int J Tuberc Lung Dis 1998; 2: 265-71.
2. Tuberculosis Research Centre. Shortening short course chemotherapy: A randomized clinical trial for treatment of smear positive pulmonary tuberculosis patients with regimens using ofoxacin in the intensive phase. Indian J Tuberc 2002; 49: 27-38.
3. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, et al. Moxifoxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-6.
4. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, Vernon AN, et al. Moxifoxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-4.
5. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, et al. Early and extended bactericidal activity of levofoxacin, gatifoxacin and moxifoxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
6. Hu Y, Coates AR, Mitchison DA. Sterilising activities of fuoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-7.
7. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifoxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-5.
8. Niemi M, Backman JT, Fromm JF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
9. Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999; 48: 168-79.
10. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifoxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl B): 83-90.
11. Nijland HMJ, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, et al. Rifampicin reduces plasma concentrations of moxifoxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-7.
12. Weiner M, Burman W, Luo C, Peloquin CA, Engle M, Goldberg S, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifoxacin. Antimicrob Agents Chemother 2007; 51: 2861-6.
13. Hemanth Kumar AK, Ramachandran G. Simple and rapid liquid chromatography method for determination of moxifoxacin in plasma. J Chromatogr B 2009; 877: 1205-8.
14. Hemanth Kumar AK, Chandra I, Geetha R, Silambuchelvi K, Lalitha V, Prema G. A validated high performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. Indian J Pharmacol 2004; 36: 231-3.
15. Moussa LA, Khassovani CE, Soulaymani R, Jana M, Cassanas G, Alric R, et al. Therapeutic INH monitoring using a simple high performance liquid chromatographic method with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 181-7.
16. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162: 985-92.
17. TBTC Study 27/28 PK: Moxifoxacin pharmacokinetics during TB treatment. Available from: http://clinicaltrials.gov/ct2/show/NCT00164463, accessed on February 9, 2012.
18. Stass H, Kubzitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifoxacin, novel 8-methoxy fuoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40: 1-19.
19. Berning SE. The role of fuoroquinolones in tuberculosis today. Drugs 2001; 61: 9-18.
20. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, et al. Moxifoxacin, ofoxacin, sparfoxacin and ciprofoxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo effcacy. Antimicrob Agents Chemother 2007; 51: 576-82.
21. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodefciency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.